Research SquareMay 11, 2026Chloë K Walters, Sarentha Chetty, Thankhoe A Rants’o et al.
preprint
Abstract Background: Conventional pharmacotherapy for treatment-resistant depression (TRD) has been found to provide limited benefit in a subset of patients. Psilocybin‑assisted therapy has emerged as a promising modality due to its rapid‑acting antidepressant effects and favourable tolerability profile shown in early trials. Despite growing research interest in psilocybin‑assisted therapy the...